NYVEPRIA

This brand name is authorized in Austria, Canada, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland

Active ingredients

The drug NYVEPRIA contains one active pharmaceutical ingredient (API):

1 Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM

Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes. Read about Pegfilgrastim

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NYVEPRIA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02506238
Country: EE	Ravimiamet	Identifier(s): 1833544
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1201486001
Country: FR	Base de données publique des médicaments	Identifier(s): 68698437
Country: IT	Agenzia del Farmaco	Identifier(s): 049200013
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091343
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100444550